Redwire Secures Starfall Capacity for Orbital Pharma Foundry

DATA TRANSMISSION: ORBITAL MANUFACTURING

Redwire ($RDW) is pivoting toward heavy-lift orbital production, securing a contract for a dedicated flight on SpaceX’s Starfall reentry capsule. According to Payload, the mission—scheduled for 2028—marks the first dedicated commercial contract for the Starfall platform, which initially debuted in June with a non-contracted ride-along experiment.

The mission will be managed by Redwire subsidiary SpaceMD. The firm intends to fly up to 32 PIL-BOX drug-crystallization laboratories, representing the largest commercial microgravity research flight announced to date. PIL-BOX technology leverages the weightless environment of Low Earth Orbit (LEO) to refine pharmaceutical compounds, allowing researchers to develop more stable and effective drug formulas that are impossible to synthesize under Earth's gravity.

HARDWARE UPGRADE

To maximize the 2028 flight, SpaceMD is developing a specialized iteration of the PIL-BOX hardware optimized for the Starfall capsule’s internal architecture. Redwire is no stranger to this domain; the company has successfully operated 54 mini-labs on the International Space Station (ISS) since 2023, processing 45 unique compounds.

STRATEGIC SHIFT

The move signals a broader industry transition as the ISS nears its planned retirement. By utilizing free-flying capsules like Starfall, commercial entities bypass the bottleneck of station manifests and crew scheduling. These automated vehicles offer a rapid return-to-Earth cycle, ensuring that sensitive pharmaceutical crystals are delivered to terrestrial labs for analysis without the delays typical of multi-user orbital stations. Redwire CEO Peter Cannito stated the partnership establishes a new trajectory for industrial-scale microgravity manufacturing, moving beyond experimental batches into high-cadence production.